½ÃÀ庸°í¼­
»óǰÄÚµå
1541554

´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå º¸°í¼­ : ¼ö¼úº°, Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2024-2032³â)

Aortic Valve Replacement Market Report by Surgery (Open Surgery, Minimally Invasive Surgery), Product (Transcatheter Aortic Valve, Sutureless Valve, and Others), End Use (Hospitals, Ambulatory Surgery Centers, and Others), and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå ±Ô¸ð´Â 2023³â 102¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 250¾ï ´Þ·¯¿¡ ´ÞÇØ 2024-2032³â »çÀÌ 10.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ´ëµ¿¸Æ ÁúȯÀÇ À¯º´·ü Áõ°¡, °Ç°­ º¸Çè Á¤Ã¥ÀÇ ½ÃÇà·ü Áõ°¡, MIS ½Ã¼úÀÇ Ã¤Åà Áõ°¡ µîÀÌ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

´ëµ¿¸ÆÆÇ ġȯ¼úÀº ½ÉÀå ÁúȯÀ̳ª ¼Õ»óµÈ ´ëµ¿¸Æ ÆÇ¸·À» ±³Ã¼Çϱâ À§ÇØ ½ÃÇàÇÏ´Â ¼ö¼úÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î °¡½¿À» Àý°³ÇÏ´Â ÀüÅëÀûÀÎ °³Èä¼ú ¶Ç´Â °¡½¿À» ÀÛ°Ô Àý°³Çϰųª ´Ù¸®¿¡ Ä«Å×Å͸¦ »ðÀÔÇÏ´Â ÃÖ¼Òħ½À(MI) ¼ö¼úÀÌ ½ÃÇàµË´Ï´Ù. ÆÇ¸·¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúº´À» Ä¡·áÇÏ°í ½ÉÀåÀ» Åë°úÇÏ´Â Ç÷·ù¸¦ Á¶ÀýÇÕ´Ï´Ù. Á¤»óÀûÀÎ Ç÷·ù¸¦ ȸº¹Çϰí, Áõ»óÀ» ¿ÏÈ­Çϰí, ¼ö¸íÀ» ¿¬ÀåÇϰí, ½É±ÙÀÇ ±â´ÉÀ» À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀϹÝÀûÀ¸·Î ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ, ´ëµ¿¸ÆÆÇ¸· Æó¼âºÎÀüÁõ°ú °°Àº ½É°¢ÇÑ ´ëµ¿¸ÆÆÇ¸· ÁúȯÀ¸·Î ÈäÅë, ¼û°¡»Ý, ÇǷΰ¨ µîÀÇ Áõ»óÀÌ Àִ ȯÀÚ¿¡°Ô ±ÇÀåµË´Ï´Ù.

´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀå µ¿Çâ

´ëµ¿¸Æ ÁúȯÀÇ À¯º´·üÀÌ ´ëÁßµé »çÀÌ¿¡¼­ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áúȯ¿¡ °É¸®±â ½¬¿î °í·ÉÈ­ Àα¸ÀÇ Áõ°¡´Â Àü ¼¼°èÀûÀ¸·Î ´ëµ¿¸ÆÆÇ ġȯ¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ´ëµ¿¸ÆÆÇ ġȯ¼ú¿¡ ´ëÇÑ ÀçÁ¤Àû Áö¿øÀ» Á¦°øÇϰí ÀÇ·áºñ¸¦ Àý°¨ÇÏ´Â °Ç°­ º¸ÇèÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ëµ¿¸Æ Áúȯ, Áõ»ó, Áø´Ü ¹× ´ëµ¿¸ÆÆÇ ġȯ¼ú°ú °°Àº Ä¡·á ¿É¼ÇÀÇ ¼Õ½¬¿î ÀÌ¿ë °¡´É¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, °³½É¼ú ¾øÀÌ ´ëµ¿¸Æ ÆÇ¸·À» ±³Ã¼ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ÃÖ¼Òħ½À ¼ö¼ú(MIS)ÀÎ °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ ġȯ¼ú(TAVR)ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀϹÝÀûÀ¸·Î °³½É¼ú¿¡ Å« À§ÇèÀÌ Àִ ȯÀڵ鿡°Ô ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¼ö¼ú ÇÕº´Áõ °¨¼Ò, ªÀº ÀÔ¿ø ±â°£, ÅëÁõ °¨¼Ò, ¼ö¼ú ÈÄ °ü¸® °¨¼Ò, ºü¸¥ ȸº¹, ³·Àº °¨¿° À§ÇèÀ¸·Î ÀÎÇØ MIS ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)À» ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ¿µ»ó Áø´Ü ±â¼ú¿¡ ÅëÇÕÇÏ¿© ÇÕº´Áõ À§ÇèÀÌ ³ôÀº ȯÀÚ¸¦ ½Äº°ÇÏ°í ¼ö¼ú ¹× ¼ö¼ú ÈÄ °ü¸®¸¦ ÃÖÀûÈ­ÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±¹°¡ÀÇ Á¤ºÎ ±â°üÀº ´©±¸³ª ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¾çÁúÀÇ ÀÇ·á ½Ã¼³À» Á¦°øÇϱâ À§ÇÑ Á¶Ä¡¸¦ ÃëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Áø´Ü ±â¼úÀÇ »ó´çÇÑ °³¼±ÀÌ ½ÃÀå ¼ºÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé

  • 2023³â ¼¼°è ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀå ¼¼°è ½ÃÀå ¼ºÀå·üÀº?
  • ¼¼°è ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • COVID-19°¡ ¼¼°è ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀåÀÇ ¼ö¼úº° ½ÃÀå ºÐ¼®Àº?
  • ¼¼°è ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀåÀÇ Á¦Ç°º° ½ÃÀå ºÐ¼®Àº?
  • ´ëµ¿¸ÆÆÇ ġȯ¼ú ¼¼°è ½ÃÀå ³» ÃÖÁ¾ ¿ëµµº° ºÐ·ù´Â?
  • ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀåÀÇ ¼¼°è ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀåÀÇ ÁÖ¿ä ÁøÀÔÀÚ/±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ´ëµ¿¸ÆÆÇ ġȯ¼ú ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ¼ö¼úº°

  • °³º¹ ¼ö¼ú
  • ÃÖ¼Òħ½À ¼ö¼ú

Á¦7Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • °æÄ«Å×ÅÍ ´ëµ¿¸ÆÆÇ
  • ¹«ºÀÇÕ ÆÇ¸·
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ ¿ëµµº°

  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï »óȲ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • Anteris Technologies Ltd.
    • Boston Scientific Corporation
    • Coroneo Inc.
    • CryoLife Inc.
    • Edward Lifesciences Corporation
    • JenaValve Technology Inc.
    • LifeNet Health Inc.
    • LivaNova PLC
    • Medtronic plc
    • Thubrikar Aortic Valve Inc.
ksm 24.09.19

The global aortic valve replacement market size reached US$ 10.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.0 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The increasing prevalence of aortic diseases, rising implementation of health insurance policies, and the growing adoption of MIS procedures represent some of the key factors driving the market.

Aortic valve replacement is a surgical procedure performed to replace a diseased or damaged aortic valve in the heart. It is usually operated through the traditional open-heart surgery, which involves incising the chest or using minimally invasive (MI) methods that require smaller incisions in the chest or a catheter incorporated in the leg. It treats diseases that affect the valves and controls blood flow through the heart. It aids in restoring normal blood flow, reducing symptoms, prolonging life, and preserving the function of the heart muscle. It is generally recommended for patients with severe aortic valve disease, including aortic stenosis or aortic regurgitation, that has symptoms like chest pain, shortness of breath, and fatigue.

Aortic Valve Replacement Market Trends:

The surging prevalence of aortic diseases among the masses and the increasing aging population that is more prone to developing these medical disorders represent one of the major factors driving the demand for aortic valve replacement around the world. Moreover, the rising implementation of health insurance policies that offer financial assistance for aortic valve replacement and reduce medical expenses is favoring the growth of the market. In addition, the growing awareness about aortic diseases, their symptoms, diagnosis, and the easy availability of the treatment options like aortic valve replacement is influencing the market positively. Apart from this, there is an increase in the adoption of transcatheter aortic valve replacement (TAVR), minimally invasive surgical (MIS) procedure that helps replace the aortic valve without open-heart surgery and is generally preferred by patients who are at major risk for traditional open-heart surgery. This, coupled with the rising preferences for MIS procedures on account of fewer operative complications, shorter hospitalization, less pain, reduced postoperative care, quicker recovery, and lower risk of infection, is propelling the growth of the market. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) in imaging techniques of aortic valve replacement to identify patients who are at higher risk for complications and optimize the procedure and postoperative care is contributing to the market growth. Besides this, governing agencies of numerous countries are undertaking measures to offer quality healthcare facilities that are accessible to all. This, along with significant improvements in the diagnostic technologies, is strengthening the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global aortic valve replacement market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on surgery, product and end use.

Surgery Insights:

Open Surgery

Minimally Invasive Surgery

The report has provided a detailed breakup and analysis of the aortic valve replacement market based on the surgery. This includes open surgery and minimally invasive surgery. According to the report, minimally invasive surgery represented the largest segment.

Product Insights:

Transcatheter Aortic Valve

Sutureless Valve

Others

A detailed breakup and analysis of the aortic valve replacement market based on the product has also been provided in the report. This includes transcatheter aortic valve, sutureless valve, and others. According to the report, transcatheter aortic valve accounted for the largest market share.

End Use Insights:

Hospitals

Ambulatory Surgery Centers

Others

The report has provided a detailed breakup and analysis of the aortic valve replacement market based on the end use. This includes hospitals, ambulatory surgery centers, and others. According to the report, hospitals represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for aortic valve replacement. Some of the factors driving the North America aortic valve replacement market included extensive research and development (R&D) activities, well established healthcare facilities, integration of advanced technologies, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global aortic valve replacement market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Anteris Technologies Ltd., Boston Scientific Corporation, Coroneo Inc., CryoLife Inc., Edward Lifesciences Corporation, JenaValve Technology Inc., LifeNet Health Inc., LivaNova PLC, Medtronic plc, Thubrikar Aortic Valve Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. What was the size of the global aortic valve replacement market in 2023?
  • 2. What is the expected growth rate of the global aortic valve replacement market during 2024-2032?
  • 3. What are the key factors driving the global aortic valve replacement market?
  • 4. What has been the impact of COVID-19 on the global aortic valve replacement market?
  • 5. What is the breakup of the global aortic valve replacement market based on the surgery?
  • 6. What is the breakup of the global aortic valve replacement market based on the product?
  • 7. What is the breakup of the global aortic valve replacement market based on the end use?
  • 8. What are the key regions in the global aortic valve replacement market?
  • 9. Who are the key players/companies in the global aortic valve replacement market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Aortic Valve Replacement Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Surgery

  • 6.1 Open Surgery
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Minimally Invasive Surgery
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Transcatheter Aortic Valve
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Sutureless Valve
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgery Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Anteris Technologies Ltd.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Coroneo Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 CryoLife Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Edward Lifesciences Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 JenaValve Technology Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 LifeNet Health Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 LivaNova PLC
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Medtronic plc
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Thubrikar Aortic Valve Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦